Abstract：
OBJECTIVE: This study aimed to characterize rasburicase dosing and duration. Secondary objectives included characterizing the indication of rasburicase and identifying the utilization of prophylactic therapy for tumor lysis syndrome (TLS).
METHODS: This retrospective review included patients 0 to 89 years old admitted between 1 January 2021 and 31 December 2021, and received at least one dose of rasburicase. Patients were excluded if they were >89 years old, pregnant, lactating, or received rasburicase outpatient.
RESULTS: A total of 192 patients, 176 adults and 16 pediatric patients were included in the retrospective review. Of the total population, 184 received a fixed dose of rasburicase and 8 patients received a weight-based dose (0.15 mg/kg/dose) of rasburicase. The average dose administered was 3.4 mg for fixed and 2.99 mg for weight-based dosing. Nearly half (49.5%) the patients received rasburicase for an elevated uric acid but did not meet Cairo-Bishop criteria for TLS. Only 42.2% received at least one dose of allopurinol within 5 days prior to rasburicase and 18.8% received aggressive hydration within 72 h prior to rasburicase.
CONCLUSIONS: The majority of rasburicase administered was ordered as fixed dose for a uric acid level ≥7.5 mg/dL. Most patients did not meet criteria for laboratory or clinical TLS and less than half the patients received prophylactic allopurinol and/or aggressive hydration. These study results are supported by recent literature for fixed dose rasburicase as a safe and economical dosing strategy compared to weight-based dosing.
METHODS: This retrospective review included patients 0 to 89 years old admitted between 1 January 2021 and 31 December 2021, and received at least one dose of rasburicase. Patients were excluded if they were >89 years old, pregnant, lactating, or received rasburicase outpatient.
RESULTS: A total of 192 patients, 176 adults and 16 pediatric patients were included in the retrospective review. Of the total population, 184 received a fixed dose of rasburicase and 8 patients received a weight-based dose (0.15 mg/kg/dose) of rasburicase. The average dose administered was 3.4 mg for fixed and 2.99 mg for weight-based dosing. Nearly half (49.5%) the patients received rasburicase for an elevated uric acid but did not meet Cairo-Bishop criteria for TLS. Only 42.2% received at least one dose of allopurinol within 5 days prior to rasburicase and 18.8% received aggressive hydration within 72 h prior to rasburicase.
CONCLUSIONS: The majority of rasburicase administered was ordered as fixed dose for a uric acid level ≥7.5 mg/dL. Most patients did not meet criteria for laboratory or clinical TLS and less than half the patients received prophylactic allopurinol and/or aggressive hydration. These study results are supported by recent literature for fixed dose rasburicase as a safe and economical dosing strategy compared to weight-based dosing.
摘要：
目的：本研究旨在表征rasburicase的剂量和持续时间。次要目标包括表征rasburicase的适应症并确定肿瘤溶解综合征（TLS）的预防性治疗的利用。
方法：这项回顾性研究纳入了2021年1月1日至2021年12月31日期间收治的0至89岁患者，并接受了至少一剂rasburicase。如果患者年龄>89岁，则将其排除在外，怀孕,泌乳,或接受rasburicase门诊治疗.
结果：总共192名患者，176名成人和16名儿科患者被纳入回顾性研究。在总人口中,184名患者接受了固定剂量的rasburicase，8名患者接受了基于体重的剂量（0.15mg/kg/剂量）的rasburicase。固定给药的平均剂量为3.4mg，基于体重给药的平均剂量为2.99mg。近一半（49.5％）的患者因尿酸升高而接受rasburicase，但不符合Cairo-BishopTLS标准。只有42.2％的人在rasburicase之前的5天内接受了至少一剂别嘌呤醇，而18.8％的人在rasburicase之前的72小时内接受了积极的水合。
结论：对于尿酸水平≥7.5mg/dL，大多数rasburicase的给药顺序为固定剂量。大多数患者不符合实验室或临床TLS标准，不到一半的患者接受了预防性别嘌呤醇和/或积极的水合作用。与基于体重的给药相比，这些研究结果得到了固定剂量rasburicase作为安全且经济的给药策略的最新文献的支持。
方法：这项回顾性研究纳入了2021年1月1日至2021年12月31日期间收治的0至89岁患者，并接受了至少一剂rasburicase。如果患者年龄>89岁，则将其排除在外，怀孕,泌乳,或接受rasburicase门诊治疗.
结果：总共192名患者，176名成人和16名儿科患者被纳入回顾性研究。在总人口中,184名患者接受了固定剂量的rasburicase，8名患者接受了基于体重的剂量（0.15mg/kg/剂量）的rasburicase。固定给药的平均剂量为3.4mg，基于体重给药的平均剂量为2.99mg。近一半（49.5％）的患者因尿酸升高而接受rasburicase，但不符合Cairo-BishopTLS标准。只有42.2％的人在rasburicase之前的5天内接受了至少一剂别嘌呤醇，而18.8％的人在rasburicase之前的72小时内接受了积极的水合。
结论：对于尿酸水平≥7.5mg/dL，大多数rasburicase的给药顺序为固定剂量。大多数患者不符合实验室或临床TLS标准，不到一半的患者接受了预防性别嘌呤醇和/或积极的水合作用。与基于体重的给药相比，这些研究结果得到了固定剂量rasburicase作为安全且经济的给药策略的最新文献的支持。
